ReviewParkinson's disease2017
Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons.
Review in Parkinson's disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives.Signal transduction and targeted therapy · 2025Review
- Beyond vessels: unraveling the impact of VEGFs on neuronal functions and structure.Journal of biomedical science · 2025Review
- The therapeutic use of clonal neural stem cells in experimental Parkinson´s disease.Stem cell research & therapy · 2024Article
- Free-water: A promising structural biomarker for cognitive decline in aging and mild cognitive impairment.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- A Continuous Extension of Gene Set Enrichment Analysis Using the Likelihood Ratio Test Statistics Identifies Vascular Endothelial Growth Factor as a Candidate Pathway for Alzheimer's Disease via ITGA5.Journal of Alzheimer's disease : JAD · 2024Article
- Vascular endothelial growth factor B improves impaired glucose tolerance through insulin-mediated inhibition of glucagon secretion.World journal of diabetes · 2023Article
- Multi-omic characterization of brain changes in the vascular endothelial growth factor family during aging and Alzheimer's disease.Neurobiology of aging · 2023Article
- The Mediating Role of Inflammation in the Relationship Between α-Synuclein and Cognitive Functioning.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Embryoid Body Cells from Human Embryonic Stem Cells Overexpressing Dopaminergic Transcription Factors Survive and Initiate Neurogenesis via Neural Rosettes in the Substantia Nigra.Brain sciences · 2023Article
- Emerging role of mesenchymal stromal cells (MSCs)-derived exosome in neurodegeneration-associated conditions: a groundbreaking cell-free approach.Stem cell research & therapy · 2022Review
- Lentiviral Vectors for Ocular Gene Therapy.Pharmaceutics · 2022Review
- Selenium Effects on Oxidative Stress-Induced Calcium Signaling Pathways in Parkinson's Disease.Indian journal of clinical biochemistry : IJCB · 2022Review
- Peptides Derived from Vascular Endothelial Growth Factor B Show Potent Binding to Neuropilin-1.Chembiochem : a European journal of chemical biology · 2022Article
- Autophagy and apoptosis cascade: which is more prominent in neuronal death?Cellular and molecular life sciences : CMLS · 2021Review
- Disabling VEGF-Response of Purkinje Cells by Downregulation ofInternational journal of molecular sciences · 2021Article
- VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions.Investigative ophthalmology & visual science · 2020Article
- Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports.Frontiers in pharmacology · 2020Article
- Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer.Pathology oncology research : POR · 2019Article
- Self-assembling vascular endothelial growth factor nanoparticles improve function in spinocerebellar ataxia type 1.Brain : a journal of neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor-B (VEGF-B), when initially discovered, was thought to be an angiogenic factor, due to its intimate sequence homology and receptor binding similarity to the prototype angiogenic factor, vascular endothelial growth factor-A (VEGF-A). Studies demonstrated that VEGF-B, unlike VEGF-A, did not play a significant role in angiogenesis or vascular permeability and has become an active area of interest because of its role as a survival factor in pathological processes in a multitude of systems, including the brain. By characterization of important downstream targets of VEGF-B that regulate different cellular processes in the nervous system and cardiovascular system, it may be possible to develop more effective clinical interventions in diseases such as Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and ischemic heart disease, which all share mitochondrial dysfunction as part of the disease. Here we summarize what is currently known about the mechanism of action of VEGF-B in pathological processes. We explore its potential as a homeostatic protective factor that improves mitochondrial function in the setting of cardiovascular and neurological disease, with a specific focus on dopaminergic neurons in Parkinson's disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.